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rectly, IFN activates lymphocytes, NK cells, and macrophages,
and it enhances antigen presentation on the cell surface (Stark
et al., 1998). Therefore, IFNs are the main component of host
antiviral defense, which links the innate and adaptive wings of
the host immune system (Mossman and Ashkar, 2005).
IFNs have been shown to be induced by different pathways,
including Toll-like receptor (TLR)-dependent (TLR-3,-4, -7, and
-9) and independent (RIG-I and Mda5) pathways (Hiscott,
2007). Those inducing signals are thought to activate latent tran-
scription factors in the cytoplasm, such as interferon regulatory
factors (IRFs) and nuclear factor kappa B (NF-kB). The activated
transcription factors translocate into the nucleus and activate
IFN promoters in both a temporally and spatially controlled
manner. Among those transcription factors, IRF-3 is the central
player in the IFN system. IRF-3 is expressed constitutively but
activated immediately upon viral infection (Hiscott, 2007). Virus
infection activates cellular kinases, such as TBK-1, and leads
to the phosphorylation of IRF-3. The phosphorylation induces
a conformation change in IRF-3, which relieves autoinhibitory in-
tramolecular binding within IRF-3. The uninhibited form of IRF-3
forms a dimer, which translocates into the nucleus, and then
recruits the CBP/p300 transcriptional coactivator and activates
promoters, including IFN-b promoter. Eventually, virus-induced
phosphorylation and activation of IRF-3 lead to the protea-
some-mediated degradation of IRF-3 (Hiscott, 2007).
The produced IFN-b is secreted, and it binds to IFN receptors on
cell surfaces. This binding causes cascades of phosphorylation
events of Janus kinase (JAK) as well as signal transducer and
activator of transcription (STAT) proteins, leading to the nuclear
translocation of phosphorylated STAT complex (Katze et al.,
2002). Binding of the complex to the IFN-stimulated response
element (ISRE) within several promoters initiates transcription
of interferon-stimulated genes (ISGs) (Mossman and Ashkar, 2005;
Taniguchi and Takaoka, 2002). The protein products of these ISGs
subsequently function to control virus replication and propagation.
One of the induced ISG products, IRF-7, is further activated by virus
infection and induces the full array of IFNs cooperatively with IRF-3,
resulting in the induction of a larger subset of ISGs (Hiscott, 2007).SUMMARY
A conserved herpesviral kinase, designated ORF36
in murine g-herpesvirus 68 (MHV-68), plays multiple
vital roles in the viral life cycle. Here, we show by
screening mutant viruses that ORF36 counteracts
the antiviral type I interferon (IFN) response. ORF36
specifically binds to the activated form of interferon
regulatory factor 3 (IRF-3) in the nucleus, inhibiting
IRF-3 interaction with the cotranscriptional activator
CBP and thereby suppressing the recruitment of
RNA polymerase II to the interferon b promoter.
The anti-IFN function of ORF36 is conserved among
herpesvirus subfamilies, although the conserved
kinase activity is not absolutely required for this func-
tion. MHV-68 lacking ORF36 induces a greater inter-
feron response and is attenuated in vitro and in vivo,
where acute viral infection in the lung and latency in
the spleen are compromised. Our data suggest that
herpesviruses have evolved within their conserved
kinase an anti-IFN activity critical for evasion of
host immunity and for persistence.
INTRODUCTION
Viral infection induces a variety of immune responses in the host
that control viral replication. In the absence of pre-existing adap-
tive immunity, the nonspecific innate immune responses are crit-
ical for restricting viral invasion and replication. Type I interferons
(IFNs), a family of cytokines that includes IFN-b and multiple
IFN-a species, are likely to be the most critical components of
the innate immune defense against viruses. The secretion of
IFNs by virus-infected cells is the foremost step of activating
an antiviral state through autocrine and paracrine signaling (Ta-
niguchi and Takaoka, 2002). Direct antiviral effects of IFN include
inhibition of viral RNA expression (Li et al., 1998), degradation of
viral mRNA (Player and Torrence, 1998), inhibition of viral proteinvier Inc.
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antiviral immune responses. In proportion to the importance of
the IFN system in controlling viral infection and replication,
viruses have developed a variety of strategies to antagonize
the system. Herpesviruses are large DNA viruses that can estab-
lish a lifelong persistence in a host by evading the host immune
surveillance and can cause various diseases during their persis-
tent infection. Thus, understanding the mechanism of herpesvi-
ral immune evasion is essential in controlling the herpesviral
diseases. To investigate the immune evasion mechanisms of
tumorigenic g-herpesviruses, we used an animal model, murine
g-herpesvirus 68 (MHV-68), which is biologically and genetically
related to the human g-herpesviruses. Through screening of the
mutant library of MHV-68 in IFN receptor knockout mice, we
found that the conserved herpesviral kinase ORF36 suppresses
the IFN-mediated response by inhibiting IRF-3. This inhibitory
function, although it does not absolutely require the conserved
kinase activity, is shared by the ORF36 homologs among
herpesvirus families. Therefore, we have identified a function of
the conserved herpesviral kinase that is essential for herpesvirus
to evade host immune surveillance and persist in a host.
RESULTS
Identification of ORF36 as a Necessary Gene of MHV-68
to Counteract IFN Response
To systematically analyze the role of viral genes in virus-host
interaction, we generated a random insertion mutant library of
Figure 1. Identification of MHV-68 Mutants
Impaired in Counteracting IFN Response
(A) Growth of mutants by acute infection in the lung and
latent infection in the spleen of normal BALB/c mice. The
ratios of in vivo to in vitro replication of each mutant are
shown. The ratio of mutant that shows the same level of
replication in vivo and in vitro, relative to the other mutants
in a pool, is defined as 1. Individual mutants in a pool are
labeled with the numbers 1 to 10. Mutant 6 is the ORF36
null mutant (36T).
(B) The same pool of mutant viruses was used to infect
IFNAR/ mice, and the same analysis as (A) was per-
formed.
(C) Acute replication of MHV-68 in the lung after infection
with WT and 36T individually.
(D) Latency establishment of MHV-68 in the spleen after
infection with WT and 36T individually.
I.C., infectious center. sp., splenocytes. Four mice per
group and per time point. Data are represented as
mean + SD.
MHV-68 by in vitro Mu transposase-mediated
signature-tagged mutagenesis (Song et al.,
2005). The signature tag allows simultaneous
screening of multiple mutants in vivo by tagging
each mutant with a unique short DNA sequence
for PCR-mediated identification and quantifica-
tion. We conducted in vivo screening to identify
viral genes that counteract antiviral IFN
response, which is the first line of host immune
defense. A pool of MHV-68 mutants was in-
fected into BALB/c mice or type I interferon receptor knockout
mice (IFNAR/). Each mouse was infected with a total of 500
plaque-forming units (pfu) of mixed mutant viruses with distinct
tags (50 pfu/mutant). The in vivo growth of mutants was analyzed
for acute replication in the lung at 7 days postinfection (dpi) and
for establishment of latency in the spleen at 14 dpi by real-time
quantitative PCR (q-PCR) as previously described (Song et al.,
2005). After comparing the growth of each mutant in two groups
of mice, one mutant virus was identified to show significant
attenuation (<1/50 of average growth of mutants) in normal
mice and enhanced growth (10-fold higher than average
growth of all mutants) in IFNAR/ mice in both acute replication
in the lung and latency in the spleen (Figures 1A–1B). The mutant
virus had a transposon insertion in the orf36 region (nucleotide
52925 in U97553, corresponding to the 27th amino acid [aa] in
the total 437 aa protein).
To confirm the screening result using the pooled mutant infec-
tion, BALB/c and IFNAR/ mice were infected with 50 pfu of
either wild-type (WT) or ORF36 null transposon mutant (36T)
MHV-68. With 50 pfu/mouse infection, the peak time of acute
replication in the lung was determined as 9 dpi in a separate
experiment. Thus, at the peak time of acute replication in the
lung and latency in the spleen (14 dpi), the organs were har-
vested and analyzed for infectious/reactivatable virus and viral
genome copy number. The 36T was attenuated in normal
BALB/c mice (1/400 of WT in both acute and latent replication)
(Figures 1C–1D). However, its attenuation was significantly
rescued in IFNAR/ mice (1/10 of WT in acute and 1/50 ofCell Host & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc. 167
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the lack of ORF36 expression delays, but does not completely
impair, the establishment of g-herpesvirus latency.
Next, we analyzed the 36S for its capacity to elicit an adaptive
T cell immune response, which has been known to control the
in vivo replication of MHV-68 (Braaten et al., 2005). To monitor
the virus-specific CD8 T cell response, we used tetrameric
reagents against two well-defined MHV-68 epitopes, ORF6487-495/
Db and ORF61524-531/K
b. The absolute numbers of ORF6487-495/
Db- and ORF61524-531/K
b-specific CD8 T cells at the mucosal
site of infection (lung) (Figure 2C) were reduced 10- to 100-fold
in 36S-infected mice at 14 dpi, but no differences in the size of
the response were found at 21 dpi. The analysis of spleen cells
(Figure 2D) showed that the numbers of MHV-68-specific CD8
T cells were slightly reduced in 36S-infected mice at 14 dpi, but
they were comparable in 36S- or WT-infected mice at 21 dpi,
a time point when 36S- and WT-infected mice show similar
levels of latency (Figure 2A). These data suggest that the magni-
tude of the early MHV-68-specific CD8 T cell response is reduced
in 36S-infected mice as a consequence of its reduced replication
in lung and delayed latency in spleen.
ORF36 Inhibits IRF-3-Mediated Activation
of Interferon b Promoter
Virus-infected cells produce a mixture of IFNs depending on the
cell type. In general, fibroblast and epithelial cells predominantly
produce IFN-b, whereas dendritic cells, leukocytes, and macro-
phages express multiple IFN-a (Katze et al., 2002). For efficient
IFN response, IFN-b-producing cells mainly rely on autocrine
feedback, but IFN-a-producing cells constitutively express
IRF-7 to rapidly produce high levels of IFN-a (Mossman and Ash-
kar, 2005). Since intranasal infection of MHV-68 can reach both
types of cells, we first investigated the effect of ORF36 expres-
sion on the activity of IFN-b promoter, which is a common
denominator in both systems (Hiscott, 2007).
While the IFN-b promoter was induced by the known transac-
tivators, such as IRF-3, IRF-7, or NF-kB, ORF36 specifically in-
hibited the IRF-3-mediated activation of IFN-b promoter in
a dose-dependent manner (Figure 3A). These data suggest
that ORF36 may inhibit the production of IFN-b through IRF-3.
We further pursued this possibility by testing upstream activa-
tors of IRF-3 signal transduction pathway, such as TANK-
binding kinase 1 (TBK-1), Toll-like receptor 4 (TLR-4), or Sendai
virus infection. TBK-1 phosphorylates and activates IRF-3 upon
viral infection (Sharma et al., 2003). TLR-4 detects microbial
invasion and activates IRF-3 pathway (in this study, we used
a constitutively activated form of TLR-4 by the conjugation
with extracellular domain of CD4 [Doyle et al., 2002]). Sendai
virus infection is a potent activator of IFN pathway (Lin et al.,
1998). As shown in Figure 3B, all three inducers successfully
activated IFN-b promoter, but ORF36 inhibited these activations
in a dose-dependent manner. These data suggest that ORF36
can inhibit the antiviral signal transduction pathway from viral
invasion detection to IFN-b promoter activation by inhibiting
the function of IRF-3.
Consistently, ORF36 inhibited the downstream reporter (ISRE-
luc; IFN stimulatory response element) of IFN receptor signaling
when it was activated by the TBK-1 overexpression, suggesting
that the inhibitory effect of ORF36 can significantly reduce theWT in latent replication). Therefore, the attenuation of 36T in
normal mice and the partial recovery of its attenuated growth
in IFNAR/ mice are due to the intrinsic growth defect of 36T
in vivo, rather than by an unexpected effect of infection with
pooled mutants. Furthermore, these data validate the effective-
ness of our screening method of using the pool of mutants to
identify critical viral genes in virus-host interaction.
Lack of ORF36 Delays the Establishment
of Splenic Latency
To further analyze the role of ORF36 in the establishment of
MHV-68 latency, we generated a mutant virus with a nonsense
mutation on the 30th aa of ORF36 (36S) and analyzed the estab-
lishment of splenic latency at 14 and 21 dpi after intranasal infec-
tion with WT or 36S. In the spleen of 36S-infected mice at the
peak of latency (14 dpi), latently infected cells were almost unde-
tectable (Figure 2A). This represents at least a 104-fold decrease
in latency compared with that of the WT virus. There was also no
evidence of the latency-associated splenomegaly normally
driven by MHV-68, which resembles lymphoproliferative re-
sponses that occur in humans during infectious mononucleosis
(Sunil-Chandra et al., 1994) (Figure 2B). However, the analysis
of the number of latently infected cells at 21 dpi showed that
Figure 2. Analysis of the In Vivo Response to 36S
C57BL/6 mice were intranasally infected with 1000 pfu of WT or 36S.
(A) The number of latently infected spleen cells was determined using an infec-
tious center assay at 14 and 21 dpi.
(B) Analysis of spleen cell numbers at 14 and 21 dpi.
(C) Absolute numbers of CD8-positive ORF6487–495/D
b (left panel) and
ORF61524–531/K
b (right panel) in the lung of infected mice.
(D) Absolute numbers of CD8-positive ORF6487–495/D
b (left panel) and
ORF61524–531/K
b (right panel) in the spleen of infected mice.
Five mice per group and per time point. Data are represented as mean + SD.vier Inc.
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Furthermore, the inhibitory effect of ORF36 on IFN-b promoter
can be reversed by the overexpression of either TBK-1 or IRF-3
(Figure 3D). In contrast, the inhibition by the dominant-negative
form of IRF-3 (IRF-3 dDBD, which lacks the DNA-binding domain
but maintains interaction and activation domain) can be reversed
by IRF-3, but not by TBK-1. This prompted us to test whether
ORF36 inhibits the function of IRF-3 directly.
ORF36 Inhibits the Interaction between IRF-3 and CBP
To further elucidate the inhibitory mechanism of ORF36, we
investigated the effect of ORF36 on each step of IRF-3-mediated
activation of IFN-b promoter. We first found that increasing the
expression of ORF36 has no effect on the expression level of
IRF-3 and the phosphorylation of IRF-3 mediated by TBK-1
(Figure S1A available online). In fact, activated IRF-3 by TBK-1
Figure 3. Impacts of ORF36 on IFN Activa-
tion Pathway
(A) The effect of ORF36 expression on the activa-
tion of IFN-b reporter, which is induced by the
cotransfected plasmids expressing IRF-3, IRF-7,
or NF-kB (p65), respectively.
(B) The effect of ORF36 expression on the activa-
tion of IFN-b reporter, which is induced by
upstream activators of IRF-3 signal transduction
pathway, TBK-1, TLR-4, and Sendai virus infec-
tion.
(C) The effect of ORF36 expression on the activa-
tion of interferon stimulatory response element
containing reporter.
(D) The effect of ORF36 and the dominant-nega-
tive form of IRF-3 (IRF-3 dDBD) expression on
the activation of IFN-b reporter induced by TBK-1
expression and the effect of TBK-1 or IRF-3 over-
expression in addition to ORF36 or IRF-3 dDBD.
All of the reporter assays were performed in
human 293T cells, and the data are represented
as mean + SD.
overexpression translocates into the
nucleus, but ORF36, which localizes in
the nucleus, did not affect this transloca-
tion (Figure 4A). Consistently, when we
activated IFN-b promoter with IRF-
3(5D), which mimics the phosphorylated
and activated form of IRF-3 by mutation
of the five serine/threonine at the C
terminus to aspartic acid (Lin et al.,
1999), ORF36 can inhibit IRF-3(5D)-
mediated activation of IFN-b promoter
(Figure S1B). Altogether, these data
clearly demonstrate that ORF36 inhibits
a step downstream of IRF-3 nuclear
translocation.
To test whether ORF36 can inhibit the
transactivation function of IRF-3 bound
to DNA by a heterologous DNA-binding
domain, we analyzed the activation of
a reporter controlled by the GAL4-
binding site and the GAL4-DBD fused form of IRF-3. ORF36 still
inhibited the activation of the reporter (Figure S1C), implying that
ORF36 interferes with the transactivation function of IRF-3 inde-
pendently of the DNA-binding activity of IRF-3. Next, we exam-
ined whether ORF36 can physically interact with IRF-3. Although
we could not detect any interaction between ORF36 and the
inactive native form of IRF-3, a physical interaction was
observed between ORF36 and IRF-3(5D), representing an acti-
vated form of IRF-3 (Figure 4B). These data suggest that
ORF36 may bind to the activated IRF-3 during the viral infection.
Therefore, to further confirm the interaction between active
IRF-3 and ORF36 during the natural infection of MHV-68, we
constructed a recombinant MHV-68, in which triple FLAG
epitope coding sequence is inserted into the 50 of the ORF36
gene in MHV-68 genome, thus expressing FLAG-tagged
ORF36 during viral replication. Infection of the recombinantCell Host & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc. 169
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(A) Subcellular localization of IRF-3 upon TBK-1/ORF36 expression in 293T cells. Anti-FLAG and anti-mouse Alexa405 (blue) for FLAG-tagged ORF36; anti-HA-
FITC (green) for HA-tagged TBK-1; anti-IRF-3 and anti-rabbit Cy3 (red) for endogenous IRF-3.
(B) Interaction between ORF36 and the native or activated form of IRF-3 by coimmunoprecipitation assay. The 293T cells were transfected with the plasmids
expressing the indicated proteins (bottom) and lysed and analyzed at 48 hr posttransfection as described in method. IP, immunoprecipitation using antibody
against indicated epitope. IB, immunoblot using antibody against indicated epitope.170 Cell Host & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc.
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Herpesviral Kinase Inhibits IFN through IRF-3(C) Interaction between the endogenous IRF-3 activated upon viral infection and the FLAG-tagged ORF36 expressed from MHV-68 during natural infection. The
293T cells were uninfected (mock) or infected with a recombinant MHV-68 expressing FLAG-tagged ORF36 at MOI = 10 and harvested and analyzed at 24 hr
postinfection (hpi).
(D) Interaction between the endogenous IRF-3 and CBP in the absence/presence of TBK-1/ORF36 in 293T cells.
(E) The effect of ORF36 on the recruitment of CBP and RNA Pol II transcription complex to the IFN-b promoter in the transfected 293T cells or infected NIH3T12
cells. (Top) Relative amount of the IFN-b promoter precipitated by anti-CBP or anti-Pol II, quantitated by q-PCR. (Bottom) The PCR products were run on agarose
gels. A set of representative data is shown here. Data are represented as mean + SD. n.s., not significant. *p < 0.05.Cell HoORF36) (Gershburg and Pagano, 2008). We tested whether this
anti-IFN function of ORF36 is also conserved. When we ex-
pressed the homologs of ORF36, all of the homologs inhibited
the TBK-1-mediated activation of IFN-b promoter in a dose-
dependent manner (Figure 5A). Further, when the production of
IFN-b was induced by treating cells with double-strand RNA
(ds polyIC), mimicking the infection of RNA viruses, all of the
homologs suppressed the activation of IFN-b promoter
(Figure 5D). The ORF36 homologs also suppressed the produc-
tion of endogenous IFN-b and downstream effectors (e.g., Mx1)
after selecting the transfected cells by drug resistance, due to
the low efficiency of transfection (Figure 5B). Collectively, these
data suggest that the anti-IFN function of ORF36 may be also
conserved among the conserved herpesviral kinases.
Subsequently, the next question was whether this inhibitory
activity requires the conserved kinase function of ORF36. We
constructed a kinase null mutant of ORF36 by mutating the invar-
iantly conserved lysine residue in catalytic core to glutamine
(K107Q), and the kinase activity is indeed knocked out in the
mutant (Tarakanova et al., 2007). This kinase null mutant of
ORF36 still inhibited the IFN-b reporter, although less potently
than it did with the wild-type (Figure 5B–5D). Consistently, the
part of ORF36 containing conserved kinase domain was suffi-
cient, but not necessary, for binding to IRF-3 (Figure S2C). The
same inhibition was also observed with the kinase null mutant
of EBV BGLF4 (K102I) (data not shown). Although there is
a possibility that the kinase activity may indirectly contribute to
the anti-IFN function of ORF36, these data suggest that the
kinase activity of ORF36 is not absolutely required for inhibition
of IFN-b promoter by ORF36.
Kinase-Dependent/Independent Function of ORF36
Is Required for Efficient Replication of MHV-68
The ChIP data suggest that MHV-68 without functional ORF36
induces more transcription complex recruitment to IFN-b
promoter, which will lead to more IFN-b production. Previously,
we have found that 36T was attenuated even in in vitro cell
culture systems (Song et al., 2005). Thus, we hypothesized
that MHV-68 without functional ORF36 may induce more anti-
viral IFN response than wild-type, and this may lead to the atten-
uation of ORF36 null viruses. Indeed, ORF36 null mutant viruses
induced more IFN-b and ISRE response than did wild-type at the
same multiplicity of infection (MOI = 0.05) (Figure S3A). This
induction was proportional to the extent of viral replication
because both WT and the mutants induced more IFN reporter
activity at higher MOI (data not shown). To further confirm the
specific phenotype of ORF36 null mutants, we generated addi-
tional mutant viruses: another nonsense mutant of ORF36
(N36S, nonsense mutation on the 107th aa), the kinase null
mutant of ORF36 (36KN, K107Q), and wild-type revertant of
ORF36 null mutant (36R). Like the other ORF36 null mutants,MHV-68 at high MOI caused the phosphorylation/activation of
endogenous IRF-3, and, consistent with Figure 4B, the FLAG-
tagged ORF36 expressed from the virus bound to this slower-
migrating phosphorylated IRF-3 (Figures 4C and S1E). These
data suggest that, during the natural infection of MHV-68, the
host may detect/inhibit the infection of MHV-68 through the acti-
vation of IRF-3, but the ORF36 of MHV-68 can counteract this
antiviral defense of host by directly binding to the phosphory-
lated/activated IRF-3. Furthermore, purified ORF36 from
bacteria can bind to in vitro translated IRF-3(5D), supporting
the direct interaction between ORF36 and the activated IRF-3
(Figure S2A).
Through the binding assay of IRF-3 deletion mutants to
ORF36, we found that the IRF association domain (IAD, aa
193–350) of IRF-3 is necessary and sufficient for binding to
ORF36 (Figure S2B). The IAD domain has been shown to be
required for binding to CBP as well as dimerization (Qin et al.,
2005), suggesting that the binding of ORF36 to IRF-3 may inhibit
the interaction between the activated IRF-3 and CBP inside the
nucleus. Therefore, we investigated whether the physical
binding between ORF36 and IRF-3 affects the interaction
between IRF-3 and CBP. When the activated form of IRF-3
was coexpressed with CBP, both IRF-3 and CBP were coimmu-
noprecipitated reciprocally. However, in the presence of ORF36,
the amounts of coimmunoprecipitated IRF-3 and CBP were
significantly reduced (Figure S1D). Indeed, when we overex-
pressed TBK-1, endogenous IRF-3 bound to CBP. ORF36 in-
hibited this interaction, suggesting that ORF36 may inhibit the
recruitment of CBP by IRF-3 to IFN-b promoter (Figure 4D).
We further analyzed the recruitment of CBP and RNA poly-
merase II (Pol II) to IFN-b promoter by performing chromatin
immunoprecipitation (ChIP) analysis of IFN-b promoter using
anti-CBP and anti-Pol II antibody. As shown in Figure 4E, over-
expression of TBK-1 induced occupancy of IFN-b promoter
with both CBP and Pol II. However, when ORF36 was coex-
pressed, the recruitment of both CBP and Pol II was significantly
reduced, indicating that ORF36 inhibited the recruitment of
general transcription complex to IFN-b promoter by activated
IRF-3. Moreover, there was more recruitment of CBP and Pol II
to IFN-b promoter in the mutant virus-infected cells than in the
wild-type infected cells. Taken together, all of the data suggest
that ORF36 binds to active IRF-3 in the nucleus and inhibits
the IRF-3-mediated recruitment of general transcription complex
to IFN-b promoter, thus inhibiting IFN-b production.
Anti-IFN Function of ORF36 Is Conserved
in Herpesviruses
ORF36 is a kinase conserved among all of the subfamilies of
herpesvirus, e.g., a (herpes simplex virus [HSV] UL13), b (human
cytomegalovirus [HCMV] UL97), and g (Epstein-Barr virus [EBV]
BGLF4 and Kaposi’s sarcoma-associated herpesvirus [KSHV]st & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc. 171
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However, both 36KN and 36R showed similar phenotype to wild-
type, supporting the specificity of ORF36 null phenotypes.
Next, we investigated the importance of antiviral IFN response
in controlling the in vitro replication of MHV-68 by generating
stable cell lines that express either IRF-3 dDBD or IRF-3(5D). All
ORF36 null mutants, but not 36R, showed attenuated growth in
the parental cell line. Their attenuated growth was significantly
rescued in the cells expressing IRF-3 dDBD and further reduced
in the cells expressing IRF-3(5D) (Figures 6B and S3B). Further-
more, the growth of 36T and 36S was also attenuated in primary
mouse embryonic fibroblast (MEF) cells, but this attenuation
was also rescued in MEF cells derived from IFNAR/ mice
(Figure S3B). Interestingly, 36KN also showed similarly attenuated
growth like ORF36 null mutant viruses in vitro (Figure 6B), although
it did not significantly induce IFN response (Figure 6A). Collec-
tively, these data suggest that ORF36 is required for MHV-68 to
counteract IFN response and to grow efficiently in vitro.
Figure 5. Impact of ORF36 Homologs
and Kinase Null Mutant on IFN Activation
(A) The effect of homologs of ORF36 in all subfam-
ilies of herpesvirus—a (HSV-1 UL13), b (HCMV
UL97), and g (EBV BGLF4 and KSHV ORF36)—
on the activation of IFN-b reporter induced by
TBK-1 expression in human 293T cells.
(B) The effect of homologs of ORF36 on the
production of IFN-b and the transcription of IFN-b
and Mx1 induced by ds polyIC treatment. The
murine NIH 3T3 cells were transfected as indi-
cated and selected for 3 days with 6 ug/ml of puro-
mycin by the cotransfected pBabe-puro. At 3 days
after selection, the transfected/selected cells were
treated with 10 ug/ml of ds polyIC in liposome
complex. At 1 day posttreatment, cell supernatant
and RNA extracted from the cells were analyzed
for endogenous IFN-b production by enzyme-
linked immunosorbent assay (ELISA) (top) and
transcription level of IFN-b (middle) and Mx1
(bottom) by q-PCR.
(C) The effect of ORF36(K107Q), a kinase null
mutant of ORF36, on the activation of IFN-b
reporter induced by TBK-1 in human 293T cells.
(D) The effect of homologs and a kinase null
mutant of ORF36 on the activation of IFN-b
reporter with or without induction by ds polyIC
treatment in NIH 3T3 cells.
Data are represented as mean + SD. *p < 0.05.
Next, we investigated whether the
same phenomenon happens in vivo.
When we measured IFN levels in the
lung of WT and 36S-infected mice,
however, we could not detect any signif-
icant level of IFN-b production by ELISA
to measure secreted IFN-b or by q-PCR
to measure the transcription of IFN-
b (data not shown). This may be due to
the extremely low level of IFN-b produc-
tion after MHV-68 infection because it is
known that MHV-68 is a poor inducer of
IFN production in vivo (Weslow-Schmidt et al., 2007). Knocking
out ORF36 may not be enough to increase IFN in the entire
lung to measurable levels by our assay systems, but it may cause
a significant difference in IFN level only at the microenvironment
level. Thus, we attempted to measure the transcript level of ISGs,
such as Mx1 and IRF-7, as representatives of the amplified down-
stream effectors of IFN-signaling pathway (Doyle et al., 2002). In
the same RNA harvested from either WT or 36S-infected lung, we
detected a similar level of Mx1 and IRF-7 (Figure 6C), showing
that 36S can induce the same level of ISG response to WT even
when its replication was severely attenuated in vivo. Taken
together, these data suggest that MHV-68 without ORF36 may
induce more antiviral IFN response in vivo as well as in vitro
than does wild-type at the same level of viral replication.
We next examined the phenotype of ORF36 null mutants by
infecting wild-type and mutant MHV-68 into normal and
IFNAR/ mice. During the acute replication of MHV-68 in the
lung, 36R replicates just like WT, but both N36S and 36KN172 Cell Host & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc.
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Cell HosDISCUSSION
The critical role of the IFN system in defending the host from viral
invasion can be attested by the diverse antagonistic strategies of
various viruses. Herpesviruses have developed multiple ways to
counteract this critical antiviral host response (Mossman and
Ashkar, 2005; Stevenson and Efstathiou, 2005). Here, we
identified a function of a conserved herpesviral protein that
antagonizes IFN response during viral replication through the
systematic screening of MHV-68 mutant library in mice with
different genetic backgrounds. As in this study, screening pools
of mutant viruses in hosts with different genetic backgrounds will
provide an efficient screening environment with competition
among viruses, which will expedite the identification process.
Furthermore, by combining this genetic screening with biolumi-
nescence whole-body imaging, screening and validation
processes can be accelerated.
Many viral and cellular proteins have been shown to be phos-
phorylated by ORF36 homologs, including ORF36 itself and
elongation factor 1d. Multiple functions of ORF36 homologs
have been proposed in the various stages of viral life cycle,
such as cellular and viral gene regulation, nuclear egress, virus
maturation and replication, chromosome condensation, and
tissue tropism (Asai et al., 2007; Gershburg and Pagano, 2008;
Hamza et al., 2004; Izumiya et al., 2007; Kawaguchi and Kato,
2003; Lee et al., 2007; Michel and Mertens, 2004). The ORF36
also plays a major role in sensitizing g-herpesvirus to nucleoside
analog drugs, such as ganciclovir (Davis et al., 2007). However,
the biological significance of many of the proposed targets and
functions has not been clearly demonstrated in the life cycle of
the virus during natural infection in vivo. In this study, we identi-
fied a function of ORF36 via an unbiased screen. The biological
significance of this function in the virus life cycle can be demon-
strated by the attenuation of the ORF36 null mutant in normal
cells and mice and the significant rescue of that attenuation in
IFNAR/ cells and mice.
Intriguingly, ORF36 interacts only with active IRF-3, which
localizes in the nucleus. The finding is further supported by the
nuclear localization of ORF36 (Figure 4A) and the binding of
ORF36 to IAD of IRF-3 (Figure S2B), which is buried by the auto-
inhibitory elements in inactive IRF-3 (Qin et al., 2005). It may
represent the beauty of viral evolution: the virus targets only
the activated form of IRF-3, rather than all IRF-3 molecules.
The majority of IRF-3 in the cell is inactive form. By targeting acti-
vated IRF-3 specifically, the virus can achieve the inhibitory goal
more efficiently with a small amount of ORF36 proteins.
Through the point and deletion mutant study of ORF36 protein
in vitro, we found that the kinase domain of MHV-68 ORF36 is
sufficient, but not necessary, for this inhibition (Figures 5 and
S2C). Consistently, the mutant MHV-68 without functional
kinase did not significantly induce the production of IFN
response (Figure 6A). However, MHV-68 with the kinase null
mutation did not replicate competently both in vitro and in vivo,
and this attenuated growth was significantly rescued when the
antiviral IFN response was compromised (Figures 6B, 6D,
and 6E). These data suggest that ORF36 counteract antiviral
IFN responses by both kinase-dependent and -independent
manners. Although the kinase activity was not absolutely
required for ORF36 to interact with IRF-3 and to suppress thewere significantly attenuated (1/1000 and 1/100 of WT by
infectious viral titer, respectively) (Figure 6D). However, N36S,
but not 36KN, could be partially rescued in the IFNAR/ mice
(1/100 by infectious viral titer). Therefore, during acute infection
in the lung, it appears that the anti-IFN function of ORF36 is
largely mediated by a kinase-independent mechanism. These
data further suggest that the kinase activity of ORF36 may play
another role in the replication of MHV-68 in the lung, indepen-
dently of anti-IFN function.
We also examined the level of viral latency established in the
spleen at 14 dpi. The 36R behaved indistinguishably from WT,
while both N36S and 36KN were attenuated in normal mice
(Figure 6E). However, in contrast to the acute replication in the
lung, the attenuation of both mutants could be mostly rescued
in the IFNAR/ mice. Thus, the kinase activity of ORF36 seems
to be mainly responsible for the anti-IFN function during the
latency in the spleen. Altogether, these data indicate that the
anti-IFN function of ORF36 is essential for viral infection in the
host and can be mediated through both kinase-dependent and
-independent mechanisms. Furthermore, the fact that the atten-
uation of N36S could not be fully restored in the IFNAR/ mice
suggests additional in vivo roles of ORF36 other than the anti-IFN
function (Lee et al., 2007; Tarakanova et al., 2007).
The Critical Role of ORF36 in the Normal Replication
Kinetics of MHV-68
For the continuous monitoring of the interaction between
MHV-68 and the host, we recently developed a bioluminescent
imaging system using a recombinant MHV-68, in which viral
M3 promoter drives firefly luciferase expression (M3FL). Our
results suggest that the replication kinetics of M3FL is similar
to that of parental wild-type MHV-68 and that M3FL is an effec-
tive model for studying the in vivo interaction of g-herpesvirus
with its host (Hwang et al., 2008). To further examine the
systemic infection of MHV-68 without ORF36, we generated
the ORF36 null stop codon mutant in the background of M3FL
(M3FL-36S). Normal BALB/c mice were intranasally infected
with 5 3 105 pfu of either wild-type M3FL or M3FL-36S, and
bioluminescent images were obtained every other day postin-
fection. In contrast to the normal progression of wild-type from
lung to spleen, which is from the primary site of infection to the
major reservoir of viral latency, the mutant virus showed rela-
tively normal acute replication in the lung but could not progress
to the spleen (Figure 7). This imaging result is consistent with the
virological assays presented in Figures 1 and 6. Furthermore,
increasing the inoculum dose by 10,000-fold (compared to
50 pfu shown in Figure 1) cannot overcome the attenuation
caused by the loss of ORF36.
However, when IFNAR/ mice were infected with 53 105 pfu
of the same viruses, there was no significant difference between
the two viruses in replication or distribution. Eventually, IFNAR/
mice infected with either M3FL or M3FL-36S succumbed
to infection during 6–8 dpi (Figure 7). This systemic analysis of
infection in vivo clearly demonstrated that the defective replica-
tion/progression of MHV-68 without ORF36 can be rescued by
inhibiting IFN response. Moreover, these data suggest that
ORF36 is the gene important for MHV-68 to counteract antiviral
IFN response in order to replicate efficiently inside immune-
competent host/cells.t & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc. 173
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(A) Bioluminescence imaging of in vivo replication of wild-type M3FL and mutant M3FL-36S in normal mice. Images at different time points are shown to represent
the peak of acute infection in the lung (D6 with 5 3 105 pfu/mouse), the transition of replication from the lung to the spleen (D10), and the establishment of viral
replication in the spleen (D14).
(B) Bioluminescence imaging of in vivo replication of wild-type M3FL and mutant M3FL-36S in IFNAR/ mice.induction of IFN-b promoter by the activated IRF-3, the kinase
activity may affect other cellular or viral proteins indirectly to
reduce the antiviral effect of IFN, augmenting direct inhibitory
effect of ORF36 on IRF-3. This may be more crucial in the real
life cycle of MHV-68, in which multiple viral proteins act together
to subvert the antiviral host defense for efficient replication.
Moreover, the fact that the ORF36 null mutant could not
be fully rescued in the IFNAR/ mice (Figure 6D and 6E)
suggests that, in addition to antagonizing the host IFN res-
ponses, ORF36 has other functions that are important for viral
replication in vivo. This is consistent with the notion that
ORF36 may have multiple functions that are important for the
efficient replication of MHV-68, such as the initiation of DNA
damage response and chromosome condensation (Lee et al.,
2007; Tarakanova et al., 2007).
IFN response is an intruder-alerting system used by host cells
to defend themselves, so invading viruses need to subvert this
alarm system immediately to infect and replicate successfully.Cell HoIt has been shown that herpesvirus virions, especially glycopro-
teins on the envelope mediating attachment and fusion of virus to
the host cells, induce interferon response (Barchet et al., 2002;
Compton et al., 2003; Dalod et al., 2002; Lund et al., 2003; Mor-
rison, 2004; Simmen et al., 2001). Although ORF36 is an early
protein expressed several hours after virus entry (Ebrahimi
et al., 2003; Martinez-Guzman et al., 2003), it was also detected
in the infectious virion (Asai et al., 2006; Bechtel et al., 2005;
Bortz et al., 2003; Overton et al., 1992; Varnum et al., 2004;
Zhu et al., 2005). Therefore, it can be released into the cytoplasm
of host cells immediately upon viral entry and may downregulate
the host IFN response to modify the host cell physiology in favor
of viral gene expression and replication. This function will
be further enhanced after ORF36 is expressed in the infected
cells. Alternatively, but not exclusively, ORF36 may also be
needed for the latent virus to efficiently reactivate. In fact,
ORF36 is one of the genes directly activated from latent KSHV
in a hypoxia-induced reactivation (Haque et al., 2006). IFNFigure 6. The Role of ORF36 and Its Kinase Activity in the IFN Induction and Replication of MHV-68 In Vitro and In Vivo
(A) The induction of IFN response by WT, N36S, 36KN, and 36R. NIH 3T3 cells were infected with WT, N36S, 36KN, or 36R virus at MOI = 0.05. At 24 hr post-
infection, cell supernatant and RNA extracted from the infected cells were analyzed for endogenous IFN-b production by ELISA (left) and transcription level of
IFN-b (middle) and Mx1 (right) by q-PCR. For ELISA, samples from three independent experiments were combined and tittered.
(B) The multistep growth curve of WT, N36S, 36KN, and 36R. Samples from two independent experiments were combined, tittered, and shown here.
(C) Transcript level of ISGs in the lung after WT or 36S MHV-68 infection examined by q-PCR. Viral genome and cellular actin transcript level were also measured
as control. Data are represented as mean + SD.
(D) Acute replication in the lung after intranasal infection of the indicated viruses in normal C57BL/6 (left) and IFNAR/ (right) mice.
(E) Latency establishment in the spleen after intranasal infection of the indicated viruses in normal C57BL/6 (left) and IFNAR/ (right) mice. I.C., infectious
center. sp., splenocytes.
500 pfu/mouse and four to five mice per group and per time point. Data are represented as mean + SD. n.s., not significant. *p < 0.05.st & Microbe 5, 166–178, February 19, 2009 ª2009 Elsevier Inc. 175
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(Barton et al., 2005). Without IFN, MHV-68 reactivated more
readily, suggesting that IFN reduces the efficiency of latent virus
reactivation. To maintain a lifelong persistent infection, MHV-68
would need to reactivate to transmit and replenish the latent
pool. Thus, MHV-68 needs to overcome the restraining effect
of IFN when it reactivates; ORF36 may also be required in this
process.
Innate Immunity Affecting Adaptive Immune Response
Herpesvirus replication is significantly affected by IFN response
both in vitro and in vivo (Barton et al., 2005; Mossman and
Ashkar, 2005). Depletion of IFN in wild-type mice during the
establishment of latency does not enhance MHV-68 reactivation
compared to the reactivation of MHV-68 in IFNAR/ mice,
suggesting that IFN-mediated innate and adaptive immune
responses during the acute infection of MHV-68 may be required
to control the reactivation of MHV-68 (Barton et al., 2005). These
data imply that the effect of IFN responses is beyond the imme-
diate nonspecific immune defense against viral invasion, further
affecting the later stage of viral replication and persistent infec-
tion in vivo. IFNs induced during viral infection have been consid-
ered to be an important link between the innate and adaptive
immune responses to viruses. For example, IFNs stimulate
antigen-presenting cells to initiate crosspriming for the activation
of CD8+ T cell response (Durand et al., 2004; Le Bon et al., 2003)
and promote proliferation and maintenance of CD8+ cytotoxic
T lymphocytes (CTL) (Agnello et al., 2003; Marrack et al.,
1999). Given the critical role of T lymphocytes in controlling
MHV-68 replication in vivo (Braaten et al., 2005; Sparks-Thissen
et al., 2004), it is possible that the anti-IFN function of ORF36 is
required not only to breach the immediate innate immune
defense upon viral infection/reactivation, but also to hinder the
development of adaptive T cell response.
The early reduction of the size of the virus-specific T cell
response, induced by a replication-attenuated 36S, correlates
with a critical role of the magnitude of antigenic stimulation for
T cell activation and differentiation (Wherry et al., 1999). Intrigu-
ingly, the ratio of the virus-specific CD8 T cell response per virus
titer is higher for 36S than for WT (Figures 2C and 2D). Further,
MHV-68 without functional ORF36 induced more IFN response
in vitro (Figure 6A) and a similar level of IFN response in vivo (Fig-
ure 6C) in comparison with WT even when its replication was
attenuated. Therefore, it is tempting to speculate that the lack of
an anti-IFN function of ORF36 in 36S contributes to induce an
enhanced innate antiviral state with higher IFN signaling in vivo
(Figure 6C) that also will add to the expansion of T cells (Kolumam
et al., 2005), even in the presence of very low levels of replicating
virus. One prediction based on this idea is that a herpesvirus
vaccine without ORF36 will be safer and more effective since it
will replicate less and still generate a strong T cell response.
The outcome of a herpesvirus infection depends on the deli-
cate balance between the strength of the host immune system
and the ability of the virus to counteract. The identification of viral
genes responsible for different immune evasion strategies of
herpesvirus will provide not only a new ground for basic mecha-
nistic research but also more opportunities to develop new
preventive and therapeutic approaches against persistent her-
pesviral infection and associated diseases.176 Cell Host & Microbe 5, 166–178, February 19, 2009 ª2009 ElseEXPERIMENTAL PROCEDURES
Preparation and Quantitation of Virus
The transposon-inserted mutant MHV-68 viruses were generated using our
BAC MHV-68 and in vitro MuA transposition system (Finzyme, Finland) as
described (Song et al., 2005). To make specific mutants of MHV-68 (i.e.,
36S, N36S, 36KN, 36R, M3FL, and M3FL-36S), a two-step allelic exchange
method was performed (Smith and Enquist, 1999).
Mouse Experiments
All animal handling was performed in accordance with University of California,
Los Angeles and Animal Research Committee guidelines and the Institutional
Animal Care and Use Committee at the Research Institute at Nationwide Chil-
dren’s Hospital. All mice were infected after anesthesia, and the infected mice
were sacrificed at 7 dpi (500–5000 pfu/mouse) or 9 dpi (50 pfu/mouse) to
measure the acute viral infection in the lung or at 14 dpi to measure the viral
latent load in the spleen.
Plasmids and Transfection
All ORF36 homologs were amplified from the viral DNA by PCR and cloned into
Entry vector of Gateway system (Invitrogen). Murine IRF-3 and IRF-3(5D) were
derived from the original pEBB-IRF-3 and pBabe-IRF-3(5D) (Doyle et al.,
2002), respectively, and further transferred into Gateway system.
Detailed Experimental Procedures and additional information are provided
in the Supplemental Data.
SUPPLEMENTAL DATA
The Supplemental Data for this article include Supplemental Experimental
Procedures and three figures and can be found with this article online at http://
www.cell.com/cell-host-microbe/supplemental/S1931-3128(09)00032-8.
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